http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9841828&dopt=Abstract
|
: J Infect Dis 1999 Jan;179(1):101-6 |
Comment in:
·
J Infect Dis. 2000 Feb;181(2):806-9
Reemergence of invasive Haemophilus
influenzae type b disease in a well-vaccinated population in remote Alaska.
Galil K, Singleton R, Levine OS, Fitzgerald MA, Bulkow L, Getty M, Perkins
BA, Parkinson A.
National Immunization Program, CDC Mailstop E61, 1600 Clifton Road, Atlanta, GA
30333, USA.
Before vaccination, Alaska Natives experienced very high rates of invasive
Haemophilus influenzae type b (Hib) disease and carriage. Vaccination with Hib
conjugate vaccine PRP-OMP (polyribosylribitol phosphate Neisseria meningitidis
outer membrane protein) began in 1991 and resulted in a sharp decline in cases.
In 1996, after switching to a different Hib conjugate vaccine, DTP-HbOC (which
combines diphtheria-tetanus-whole cell pertussis vaccines with HbOC [Hib
oligosaccharide CRM197]), cases of invasive Hib disease increased, suggesting
ongoing Hib transmission despite widespread vaccination. To determine the
prevalence of and risk factors for carriage, a cross-sectional study of
oropharyngeal Hib carriage was conducted among Alaska Native children aged 1-5
years in remote southwestern Alaska. Of 496 children with swabs taken, 46
(9.3%) were colonized with Hib. Carriage rates varied by village from 2.2% to
13.2% and by age from 6.1% in 1-year-olds to 14.7% in 5-year-olds. Crowding was
associated with Hib carriage. Widespread vaccination with PRP-OMP Hib conjugate
vaccine did not eliminate carriage in this population of Alaska Natives, and
ongoing carriage contributed to disease resurgence.
PMID: 9841828 [PubMed - indexed for MEDLINE]
ALL
INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR
GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE
KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED
AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO
VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU
ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.